Frontiers4d
NAFLD treatment in diabetes: from current dietary interventions to novel treatment
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...
EU health regulator clears use of AI tool in fatty liver disease trials
A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...
Nature6d
Non-alcoholic steatohepatitis articles from across Nature Portfolio
It is the progressive form of non-alcoholic fatty liver disease (NAFLD). NASH can lead to cirrhosis and liver cancer. Shumbayawonda et al. examine the impact of multi-parametric MRI in managing ...
Medscape4d
Nonalcoholic Steatohepatitis: Risk Factors and Diagnosis
NASH diagnostics consists of CK-18 total, CK-18 cleaved, adiponectin and resistin. NASH diagnostic panel consists of diabetes, gender, BMI, triglyceride and CK-18 total, CK-18 cleaved levels.
Frontiers2d
An integrative pharmacology-based study on the pharmacological activity and mechanism of xiaoji-chenpi formula (XCF) against MAFLD
Metabolic-associated fatty liver disease (MAFLD) is a common chronic metabolic disease worldwide that seriously threatens human health. The Xiaoji-chenpi formula (XCF), derived from QingGanSan (QGS), ...